A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. Cancer letters [Cancer Lett] Journal article | | Title | A small molecule inhibitor of NF-kappaB, dehydroxymethylepoxyquinomicin (DHMEQ), suppresses growth and invasion of nasopharyngeal carcinoma (NPC) cells. | | Author(s) | Wong JH, Lui VW, Umezawa K, Ho Y, Wong EY, Ng MH, Cheng SH, Tsang CM, Tsao SW, Chan AT | | Institution | Department of Clinical Oncology, Sir YK Pao Center for Cancer, State Key Laboratory in Oncology in South China, Hong Kong Cancer Institute and Li Ka Shing Institute for Health Sciences, The Chinese University of Hong Kong, Hong Kong. | | Source | Cancer Lett 2009 Jun 25. | | Abstract | Despite the demonstrated constitutive activation of NF-kappaB in nasopharyngeal carcinoma (NPC), the therapeutic potential of targeting this pathway has not been investigated. Here, we employed a small molecule inhibitor of NF-kappaB, DHMEQ (which mainly blocks nuclear translocation of activated NF-kappaB) and demonstrated significant inhibition of NPC cell proliferation, migration, invasion, as well as anchorage-independent growth. These antitumor effects were associated with induction of G(2)/M cell cycle arrest and apoptosis, and downregulation of NF-kappaB target genes (EGFR, cyclin D1 and survivin). This first demonstration of therapeutic benefits of NF-kappaB targeting in NPC implicates the importance of targeting this pathway in NPC. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19560263 |
|
|
| |
Advertise on this site.
| | |
|
